A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 1. Theoretical Considerations
暂无分享,去创建一个
[1] B. Faller,et al. CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs , 2011, Drug Metabolism and Disposition.
[2] R. Obach,et al. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment , 2007, Xenobiotica; the fate of foreign compounds in biological systems.
[3] K. Koeplinger,et al. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. , 1998, The Journal of pharmacology and experimental therapeutics.
[4] M. Mohutsky,et al. Irreversible enzyme inhibition kinetics and drug-drug interactions. , 2014, Methods in molecular biology.
[5] J. Crowley,et al. Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[6] A. Galetin,et al. Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4 , 2012, Drug Metabolism and Disposition.
[7] Shiew-Mei Huang,et al. Predicting Drug–Drug Interactions: An FDA Perspective , 2009, The AAPS Journal.
[8] T. Poulos,et al. Crystallization of cytochromes P450 and substrate-enzyme interactions. , 2004, Current topics in medicinal chemistry.
[9] L. Wienkers,et al. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Mibefradil through Heme Destruction , 2011, Drug Metabolism and Disposition.
[10] M. Huang,et al. Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. , 1981, The Journal of biological chemistry.
[11] B. Metcalf,et al. Catalytic inhibition of γ-aminobutyric acid-α-ketoglutarate transaminase of bacterial origin by 4-aminohex-5-ynoic acid, a substrate analog , 1975 .
[12] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[13] B. Ma,et al. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[14] W. Atkins,et al. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. , 2005, Annual review of pharmacology and toxicology.
[15] S. Hall,et al. Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations , 2001 .
[16] O. Hankinson,et al. The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil , 2008, Drug Metabolism and Disposition.
[17] G. Tucker,et al. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE , 2004, Drug Metabolism and Disposition.
[18] G. Tucker,et al. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE , 2004, Drug Metabolism and Disposition.
[19] K. Korzekwa,et al. Enzyme kinetics of oxidative metabolism: cytochromes P450. , 2014, Methods in molecular biology.
[20] A. Conney,et al. In vivo activation of zoxazolamine metabolism by flavone. , 1982, Science.
[21] Namandjé N. Bumpus,et al. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. , 2008, Chemical research in toxicology.
[22] G. Bellward,et al. Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[23] H. Kotaki,et al. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[24] Stephen Fowler,et al. In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions , 2008, The AAPS Journal.
[25] R. Silverman. Mechanism-based enzyme inactivators. , 1995, Methods in enzymology.
[26] Chuang Lu,et al. The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.
[27] S. G. Waley,et al. Kinetics of suicide substrates. , 1980, The Biochemical journal.
[28] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[29] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.
[30] D. Jones,et al. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.
[31] D. Tweedie,et al. A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data , 2014, Drug Metabolism and Disposition.
[32] R. Kitz,et al. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.
[33] C. Ernest,et al. Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.
[34] Y. Sugiyama,et al. Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4 , 2000, Pharmaceutical Research.
[35] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[36] S. Waley. Kinetics of suicide substrates. Practical procedures for determining parameters. , 1985, The Biochemical journal.
[37] Nina Isoherranen,et al. Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. , 2006, Biochemistry.
[38] Fabio Garofolo,et al. Bioanalytical Method Validation , 2004 .
[39] K. He,et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. , 1998, Chemical research in toxicology.
[40] M. Correia,et al. Inhibition of Cytochrome P450 Enzymes , 2015 .
[41] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[42] R. Sheridan,et al. Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules. , 2007, Journal of medicinal chemistry.